NATCO Pharma growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	−7.9%	+14.6%
EBITDA	−34.6%	+15.4%
Net Income	−24.7%	+25.6%
EPS (adj.)	−24.8%	+25.6%
Total Assets	+28.3%	+25.1%
Total Equity	+21.2%	+23.7%
Free Cash Flow	+16.2%	+28.9%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NATCOPHARM₹793.00

NATCO Pharma Ltd.

· Pharma & Health

₹ CrorePeersDRREDDY ZYDUSLIFE SUNPHARMA LALPATHLAB NEULANDLAB NH SAILIFE COHANCEMcap ₹14,195 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	-7.9	+14.6
EBITDA	-34.6	+15.4
Net Income	-24.7	+25.6
EPS (adj.)	-24.8	+25.6
Total Assets	+28.3	+25.1
Total Equity	+21.2	+23.7
Free Cash Flow	+16.2	+28.9

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.